Prof. Saad (CA) talks about the PROpel: Phase III trial of olaparib and abiraterone versus placebo and abi as first-line therapy for patients with mCRPC he presented at ASCO GU22.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.I agreeRead More
